GlassScriptPhysician profile
Phillip Madonia
NPI 1871685917
$14,295.88
in general payments reported to CMS, 2019-2025
44 companies · $92.02 in 2025
The $92.02 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,041 · 2020: $3,327 · 2021: $4,258 · 2022: $357 · 2023: $164 · 2024: $57.89 · 2025: $92.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,811.61 | 2019-2022 | |
| Pfizer INC. | $3,224.02 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $743.97 | 2019-2024 | Trulance |
| Astrazeneca Pharmaceuticals LP | $691.70 | 2020-2023 | Lokelma |
| Lilly USA, LLC | $249.80 | 2019-2021 | |
| Novo Nordisk INC | $146.06 | 2020 | |
| Allergan, INC. | $144.80 | 2019-2020 | |
| Amarin Pharma, INC. | $144.52 | 2019-2021 | |
| Aspira Women'S Health INC | $128.28 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $111.93 | 2019-2020 | |
| Coopersurgical, INC. | $86.66 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $78.79 | 2020-2021 | |
| Organon LLC | $63.26 | 2022-2025 | Nexplanon, Jada System |
| Mylan Pharmaceuticals INC. | $42.84 | 2021-2022 | |
| Shield Therapeutics INC | $38.51 | 2023-2024 | Accrufer |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $37.02 | 2019-2025 | |
| Lupin INC. | $36.51 | 2019-2020 | |
| Meditrina | $35.72 | 2022-2023 | |
| Exeltis, USA INC. | $34.74 | 2019-2021 | |
| Urovant Sciences INC | $34.60 | 2022 | |
| Hologic Sales and Service, LLC | $33.61 | 2023-2024 | Myosure Tissue Removal Device, Acessa Provu System |
| Zyla Life Sciences, INC. | $32.13 | 2020 | |
| Ethicon US, LLC | $31.96 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $27.90 | 2019 | |
| Mayne Pharma Commercial LLC | $26.90 | 2025 | |
| Medtronic, INC. | $26.13 | 2021 | |
| Amgen INC. | $25.07 | 2019-2021 | |
| Vivus LLC | $23.38 | 2021 | |
| Opko Pharmaceuticals, LLC | $22.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.20 | 2021 | |
| Eisai INC. | $20.09 | 2020 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Astellas Pharma US INC | $15.54 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.51 | 2022 | |
| Becton, Dickinson and Company | $14.77 | 2023 | Bd Onclarity |
| Pacira Pharmaceuticals Incorporated | $14.68 | 2021 | |
| Daiichi Sankyo INC. | $14.41 | 2021 | |
| Avion Pharmaceuticals | $13.21 | 2019 | |
| Myovant Sciences INC. | $12.24 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Madonia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.